Zevra director receives 30,000 stock options

Zevra Therapeutics director Tamara A. Favorito received a grant of stock options for 30,000 shares of common stock on June 4, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Zevra Therapeutics director Tamara A. Favorito received a grant of stock options for 30,000 shares of common stock on June 4, 2026. The options have an exercise price of $11.17, matching the Nasdaq closing price on the grant date, and expire on June 3, 2036. All 30,000 shares underlying the options vest 100% on the earlier of the first anniversary of the grant, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, subject to her continued board service. The grant was awarded as compensation under Zevra’s non-employee director compensation policy.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider FAVORITO TAMARA A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 30,000 contracts (Direct)

Footnotes (3)

F1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.
F2. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.
F3. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Key Figures

Stock options granted: 30,000 options Exercise price: $11.17 per share Underlying shares: 30,000 shares +3 more

6 metrics

Stock options granted 30,000 options Grant to director Tamara A. Favorito on June 4, 2026

Exercise price $11.17 per share Equal to Nasdaq closing price on grant date

Underlying shares 30,000 shares Common stock underlying the stock option award

Expiration date June 3, 2036 Option term end date

Post-transaction derivative holdings 30,000 options Total stock options held directly after this grant

Vesting condition 100% cliff vesting Earlier of first anniversary, pre-AGM date, or change in control

Key Terms

Stock Option (right to buy), exercise price, change in control, non-employee director compensation policy, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"The exercise price is equal to the closing price of the Issuer's common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change in control financial

"immediately prior to a change in control of the Issuer, subject in each case"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

non-employee director compensation policy financial

"pursuant to the Issuer's tenth amended and restated non-employee director compensation policy"

Nasdaq Global Select Market financial

"common stock on the Nasdaq Global Select Market on the date of grant"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Zevra Therapeutics (ZVRA) director Tamara Favorito receive in this Form 4?

Tamara Favorito received a grant of stock options for 30,000 shares of Zevra common stock. The options were awarded as compensation for her service on the board under the company’s non-employee director compensation policy.

What is the exercise price of Tamara Favorito’s new Zevra (ZVRA) stock options?

The stock options have an exercise price of $11.17 per share. This price equals the closing price of Zevra’s common stock on the Nasdaq Global Select Market on the June 4, 2026 grant date, according to the Form 4 footnotes.

How many Zevra (ZVRA) shares underlie the stock options granted to Tamara Favorito?

The option grant covers 30,000 shares of Zevra Therapeutics common stock. Following this compensation award, the Form 4 shows 30,000 derivative securities (stock options) held directly by Tamara Favorito in connection with her board service.

When do Tamara Favorito’s Zevra (ZVRA) stock options vest?

All 30,000 option shares vest 100% on the earliest of three events: the first anniversary of the grant date, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, if she continues serving on the board.

When do the Zevra (ZVRA) stock options granted to Tamara Favorito expire?

The options expire on June 3, 2036, providing a long-term window to exercise. After vesting, she may choose to exercise the options any time before this expiration date, subject to plan terms and applicable trading restrictions.

Is Tamara Favorito’s Zevra (ZVRA) Form 4 an open-market stock purchase or a compensation grant?

The Form 4 reflects a compensation grant, not an open-market purchase. The stock options were awarded under Zevra’s tenth amended and restated non-employee director compensation policy for her service on the board of directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2026 - 04:16 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FAVORITO TAMARA A

(Last)

(First)

(Middle)

C/O ZEVRA THERAPEUTICS, INC.

101 FEDERAL STREET

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$11.17⁽¹⁾	06/04/2026		A		30,000⁽²⁾		⁽³⁾	06/03/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

2. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

3. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Remarks:

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Tamara A. Favorito	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR